Viemed Healthcare (VMD) EBITDA (2018 - 2026)

Viemed Healthcare has reported EBITDA for 9 years, with the latest figure at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 11.85% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $23.4 million (up 19.79% YoY), and the FY2025 full-year result was $22.9 million, up 103.72% from the prior year.
• EBITDA for Q1 2026 stood at $4.3 million, down from $8.4 million in the prior quarter.
• The five-year high for EBITDA was $8.4 million in Q4 2025, with the low at $1.0 million in Q2 2022.
• Historically, EBITDA has averaged $3.6 million across 5 years, with a median of $3.5 million in 2023.
• Annual changes were most pronounced in 2022 — EBITDA plunged 42.45% — and 2023, when it surged 150.13%.
• Viemed Healthcare's EBITDA stood at $2.4 million in 2022, then surged by 45.97% to $3.5 million in 2023, then surged by 85.56% to $6.5 million in 2024, then rose by 29.74% to $8.4 million in 2025, then tumbled by 48.68% to $4.3 million in 2026.
• The last three EBITDA figures came in at $4.3 million (Q1 2026), $8.4 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.